new glp 1 agonist novo nordisk inks Ascendis deal to develop long-acting GLP-1, other metabolic drugs Quantity:Triple-Pack ($99) tirzepatide In patients with #obesity,

new glp 1 agonist novo nordisk inks Ascendis deal to develop long-acting GLP-1, other metabolic drugs Quantity:Triple-Pack ($99) tirzepatide In patients with #obesity,

In patients with #obesity, incretin-based therapies such as GLP-1 receptor agonists are reported to result in mean weight reductions of approximately 15 to 20% along with additional health benefits, including decreased cardiovascular

The ASA also recommends patients using GLP-1 agonists for diabetes management and to prevent hyperglycemia (high blood sugar) consider consulting with an endocrinologist before surgery

tirzepatide

Quantity:Triple-Pack ($99)

Ozempic and Trulicity